FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.